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Bovine papillomaviruses (BPVs) are oncogenic DNA viruses, which mainly induce benign lesions of cutaneous and/
or mucosal epithelia in cattle. Thirteen (BPV 1–13) different viral genotypes have been characterized so far. BPVs are
usually species-specific but BPV 1/2 may also infect equids as well as buffaloes and bison and cause tumors in these
species. BPV-induced benign lesions usually regress, however occasionally they develop into cancer particularly in
the presence of environmental carcinogenic co-factors. The major transforming protein of BPV is E5, a very short
hydrophobic, transmembrane protein with many oncogenic activities. E5 contributes to cell transformation through
the activation of the cellular β receptor for the platelet-derived growth factor (PDGFβ-r), it also decreases cell
surface expression of major histocompatibility complex class I (MHCI) causing viral escape from immunosurveillance,
and plays a role in the inhibition of the intracellular communication by means of aberrant connexin expression. E7
is considered as a weak transforming gene, it synergies with E5 in cell transformation during cancer development.
E7 expression correlates in vivo with the over-expression of β1-integrin, which plays a role in the regulation of
keratinocytes proliferation and differentiation. Additionally, E7 is involved in cell-mediated immune responses
leading to tumour rejection, in anoikis process by direct binding to p600, and in invasion process by upregulation
of Matrix metalloproteinase1 (MMP-1) expression. Studies on the role of BPV E5 and E7 oncoproteins in naturally
occurring tumours are of scientific value, as they may shed new light on the biological role of these two
oncogenes in cell transformation.
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Papillomaviruses (PVs) are small oncogenic DNA viruses
infecting humans as well as different animal species,
causing benign hyperproliferative lesions of both muco-
sal and cutaneous epithelia or malignant cancers. BPVs
belong to the PV family and infection of bovines by
BPVs is associated with the development of cutaneous
papillomas, alimentary and urinary bladder tumours.
BPVs are usually species-specific, and, even in experi-
mental conditions, do not infect any host other than the
natural one. However, BPV type 1 (BPV-1) and BPV type
2 (BPV-2) represent a well known case of cross-species
infection since they also infect equids as well as buffa-
loes and bisons [1-4]. BPV-induced benign lesions* Correspondence: borzacch@unina.it
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reproduction in any medium, provided the orusually regress, however occasionally they develop into
cancer of both epithelial and mesenchymal origin. The
major transforming protein of BPV is E5, a very small
membrane-associated protein with potent biological ac-
tivities [5]. The carcinogenic functions of E5 have been
largely investigated in vitro, however many recent find-
ings have highlighted the role of this oncoprotein also in
naturally occurring oncogenesis.
BPV E7 is considered as a transforming gene although
very little is known about E7-mediated mechanisms
underlying carcinogenesis, so far. It has been hypothesized
that BPV-E7 cooperates with E5 in cell transformation [6].
BPV has largely contributed as animal model to under-
stand the genetics of PVs, the role of the early genes in
cell transformation and still continues to do so due to
very recent discoveries in naturally occurring equine and
bovine tumours [7].tral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are of interest not only in veterinary pathology but also
from a comparative point of view. BPV E5 and E7 onco-
genes have been studied at length up-to-date opening new
scenarios about the possible role of these oncogenes in PV-
induced cell transformation.
This review, will describe in brief the biological fea-
tures of BPV E5 and E7 oncoproteins and will focus on
the activity and the expression patterns of the two onco-
proteins in vivo in naturally occurring bovine and equine
tumours.
BPV oncoproteins: general biological
characteristics
All PVs have a circular double-stranded DNA genome.
The genetic organisation of BPVs is similar to that of other
PVs. The open reading frames (ORFs) are divided into
early and late regions. The early region encodes non struc-
tural proteins from E1 to E7. The late region encodes two
structural proteins: L1 and L2. In addition, a non-coding
long control region provides the cis-regulatory elements
necessary for viral replication and transcription [8]. The
transforming activities of BPVs are due to three early viral
genes: E5, E6, and E7. The specific contribution of each
oncogene in transforming process varies between different
BPVs. Some BPVs (BPV-3,-4,-6) lack the E6 gene, al-
though they are able to give a successful infection and to
induce tumours [9].
Despite the clear evidence that E6 is an efficient trans-
forming protein in vitro [10,11], the activity of E6 in vivo
in naturally occurring tumours still remains uncertain
and needs to be investigated.
The growing body of recent studies in vivo highlights
the central role of E5 and E7 expression/activity in tumour
development strengthening the focus of this review.
E5 oncogene
The major transforming protein of BPV is E5, a very small,
membrane associated protein with different biological ac-
tivities and critical to the transformation process [5,12,13].
BPV-1 E5 is the shortest oncoprotein yet characterized
being only 44-aminoacid long [12,14,15]. Genetic and bio-
chemical studies have revealed that the E5 protein can be
divided into two distinct domains: an amino-terminal do-
main (residues 1–32), consisting of strongly hydrophobic
aminoacid residues and a single hydrophilic aminoacid,
and an hydrophilic carboxyl-terminal domain (residues
33–44). The hydrophobic domain is presumed to mediate
the association with cellular membranes and to function as
a signal-anchor domain whereas the hydrophilic domain is
believed to interact with important cellular regulatory pro-
teins [16]. In accordance with its predicted hydrophobic
composition, the E5 protein spontaneously localizes in the
membranous compartment where it is present as a dimer.The C-terminal domain is involved in E5 dimer and oligo-
mer formation. Oligomerization appears to be essential for
the transforming activity [12,17]. E5 accumulation in the
late (trans-) Golgi apparatus (GA) is critical for its mito-
genic signalling. Retention of E5 in the ER and early (cis-)
Golgi causes loss of transformation activity [18]. Mutagen-
esis analysis underscore the critical role of individual ami-
noacid residues in mediating E5 biological activities.
Several studies indicate that the hydrophobic nature of
BPV E5 and a handful of important aminoacidic residues
confer transforming activity [17]. These essential aminoa-
cids are the most well conserved among related papilloma-
viruses [19].
E5 induces cell transformation through the activation
and/or impairing of several intracellular targets involved
in cell proliferation and survival [5].
E7 oncogene
The BPV-1 E7 oncogene is a zinc binding protein 127
aminoacids long. E7 does not show a strong independent
transforming activity, but when it is coexpressed with E5,
its transformation capacity is pronouncedly increased [6].
Mutants lacking the E7 open reading frame are still able
to induce transformation but with lower efficiency [20]. It
is not clear how BPV-1 E7 contributes to cell transform-
ation as this oncoprotein, in contrast to HPV-E7, lacks the
LXCXE motif that mediates the binding to the pRB family
proteins [21]. It has been reported that the transformation
activity of BPV-1 E7 is mediated, at least in part, by its
ability to bind p600. The binding between BPV-1 E7 and
p600 contributes to cell transformation by inhibiting the
anoikis, a type of apoptosis, which is commonly encoun-
tered in cancer cells, allowing them to survive in the ab-
sence of normal cell-matrix interactions [22]. In addition,
BPV-1 E7 seems to sensitize the cells to TNF-induced
apoptosis [23,24]. On the contrary E7 is the major trans-
forming protein of BPV-4 as defined in in vitro systems
[25,26]. BPV-4 E7 contains two Cys-X-X-Cys motif and
the pRb-binding domain, both are critical for its trans-
forming activity [25].
Most of the studies on BPVs have been performed in
in vitro systems where the biological characteristics and
functions of BPV oncoproteins have been largely investi-
gated, however the functions of BPV oncoproteins
in vivo are less understood. Recent insights into E5 and
E7 biological activities strenghten the pivotal role of
these oncoproteins in cell transformation in naturally
occurring tumours.
BPV E5 and E7 in naturally occurring tumours
BPV infection is associated to cutaneous papillomas, ali-
mentary fibropapillomas and urinary bladder tumours in
cattle and to sarcoids in equids.
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Cutaneous papillomatosis is characterized by the pres-
ence of multiple benign exophitic proliferations of the
epithelia (Figure 1A). At least 11 different types of BPVs
have been identified in association with cutaneous papil-
lomas and fibropapillomas (BPV-1, BPV-2, BPV-5, BPV-
6, BPV-7, BPV-8, BPV-9, BPV-10, BPV-11, BPV-13)
[1,27,28]. When BPV-infection of the skin causes also
the transformation of dermal fibroblasts and epithelialFigure 1 Examples of BPV induced tumours in its natural host,
bovine, and in its heterologous host, horse. A. Persistent
papillomatosis of the skin in a cow. B. Diffuse papillomatosis of the
oesophagus in a cows , the arrows indicate the papillomas. C.
Multiple haemangiosarcomas and urothelial carcinoma of the urinary
bladder in a cows. D. Multiple nodular sarcoids in the paragenital
and mammary region in a horse.acanthosis, the lesion is defined as fibropapilloma. Papil-
lomas and fibropapillomas may localize in different body
sites in cattle [29].
During papilloma formation, the expression of BPV
early and late genes is strictly regulated. The virus ini-
tially infects the basal keratinocytes. The early genes are
expressed in undifferentiated basal and suprabasal layers,
determining the re-entry of spinous cells into the cell
cycle and amplification of viral DNAs in a process
termed vegetative viral replication [4]. The distribution
of BPV E5 and E7 proteins have been studied in bovine
fibropapillomas.
In bovine fibropapillomas two sites of E5 expression
have been identified within the epithelium: the cyto-
plasm of basal cells and superficial granular cell layer.
High concentrations have been noted for E5 protein in
the differentiated tumour keratinocytes. The granular
staining pattern is associated with the sites of viral cap-
sid synthesis [30]. The expression pattern of E5 and its
localization in the lesions are suggestive for E5 actively
contributing to successfull BPV (de novo) infection.
The localization in the basal layers indicates that E5
may have a role during the early stages of viral infection
and tumour development and it may lead to sustained cell
proliferation to favor virus-infected cells. Its presence in
the more differentiated layers suggests an involvement of
E5 in the late stages of the viral life cycle [6].
Interestingly, BPV-1 E5 has also been found to be
expressed in cutaneous fibropapillomas from water buffa-
loes [2]. This observation suggests that the oncoprotein
plays a role in cutaneous fibropapillomas development in-
dependently of the infected species.
Typically E5 has been detected mostly within the cyto-
plasm of infected epithelial and fibroblastic cells, further-
more, some of the cells showed accentuated staining on
one side of the nucleus, in a perinuclear region, consistent
with the localization in the Golgi apparatus (GA) [30].
In E5 expressing fibropapillomas alterations in Con-
nexin26 (Cx26) expression levels and in its intracellular
localization have been demonstrated [31]. Interestingly,
Cx26, a component of the skin connexons, colocalizes
with E5 in a juxtanuclear region. This observation sup-
ports the hypothesis for a possible role of E5 in alter-
ation of the Gap junctions intercellular communication
mediated by Cx26 dysregulation. It is likely that the
down-regulation of the gap junctions by E5 makes the
transformed cells refractory to growth inhibitory signals
from neighbouring cells [31]. It is worth noting that cu-
taneous fibropapillomas expressing E5 show hyperactiva-
tion of the PDGFβR and its downstream transforming
signals, suggesting a possible role of this cell signaling in
lesion development [32].
BPV-E7 is expressed in the cytoplasm and nucleus of
the spinous layers where vegetative BPV amplification is
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localized in the basal layers of neoplastic epithelium
where it colocalizes with E5. The co-expression of both
proteins in the basal layer of fibropapillomas suggests
that they may cooperate in controlling cell proliferation,
and it is possible that E7 expression serves to modulate
the actions of E5 on epithelial cells [6].
Remarkably, BPV-1 E7 expression in fibropapillomas
correlates with the over-expression and the aberrant ex-
pression of β1-integrin and PCNA in suprabasal epithe-
lial cells. β1-integrin is a member of the integrin family,
which has a role in the regulation of keratinocytes prolif-
eration and differentiation. The observation that the dis-
tribution of β1-integrin within the fibropapilloma was
reminiscent of the distribution of BPV-1 E7, indicates
that E7 is implicated in the induction of vegetative DNA
amplification in keratinocytes of the spinous layer [33].
Bovine fibropapillomas of the upper gastrointestinal tract
The mucosal epithelium of the alimentary canal of cattle
may be infected by BPV type 4 where it induces fibropapil-
lomas (Figure 1B) [34]. Epithelial papillomas of the upper
gastrointestinal (GI) tract can develop at every site from
the mouth to the rumen. Histologically, they have the same
features of benign fibropapillomas where the active viral
replication results in inclusion bodies visible in the nuclei
of infected cells [35,36]. Fibropapillomas regress in healthy
immunocompetent animals due to an efficient cell-
mediated immune response. Cattle feeding on bracken fern
develop upper alimentary canal cancers as a result of an
interactions between the virus and the toxic and carcino-
genic substances contained in bracken fern [8,37].
The transforming activities of BPV-4 is due to the viral
genes E5 and E7. BPV-4 E5 encodes a small hydrophobic
polypeptide similar in its length and amino acid compos-
ition to the BPV-1 E5 polypeptide (see above). BPV-4 E7
unlike BPV-1 E7 possesses the canonical Cys-X-X-Cys
motif and the pRb interaction domain, that is crucial for
its transforming ability [25]. Both proteins are expressed
in virally induced alimentary canal tumours: E5 is mostly
expressed in early development stages, on the contrary
E7 is produced throughout all stages of the fibropapil-
loma, suggesting its pivotal role in the maintenance of
the proliferative state of the epithelia and its necessary
role in cell transformation [38].
BPV-4 E5 is expressed in fibropapillomas of the alimen-
tary canal where it localizes in the basal layers [38]. Fol-
lowing viral infection of basal keratinocyte, E5 induces
down-regulation of surface MHCI expression. This is an
important observation for the notion that E5 has a role in
the establishment of BPV infection in fibropapillomas of
the alimentary canal. E5 may contribute to BPV escape
from immunosurveillance through the prevention of viral
antigen presentation to immune effector cells [39].In alimentary carcinomas E7 was uniformly detected
within the nuclei of basal and suprabasal cells and
within the cytoplasm of differentiated spinous and
granular cells, suggesting that this different intracellular
localization might correspond to different functions [6].
The more extensive analysis of vaccination and im-
mune response in relation to BPV-4 induced tumours
was indicative for the possibility that E7 has an import-
ant role in cell-mediated immune responses leading to
tumour rejection [40,41]. Experimental rejection of BPV-
4 papillomas has been achieved by immunizing cattle
with the viral protein E7, and the regressing papillomas
showed infiltrates of immune cells similar to those
observed in naturally regressing tumours.
Bovine urinary bladder tumours
Tumours of the urinary bladder in cattle are of epithelial
and mesenchymal origin (Figure 1C) [42,43] and com-
monly associated with chronic enzootic haematuria
(CEH), a syndrome caused by prolonged ingestion of
bracken fern [8]. The involvement of BPV-1/2 in urinary
bladder carcinogenesis is well recognized and the syner-
gistic relationship between the virus and carcinogens
from the fern has been experimentally reproduced [37].
The expression, localization and oncogenic activity of
BPV E5 has been largely studied in BPV induced urinary
bladder tumours. BPV E5 is expressed in the cytoplasm of
both basal and suprabasal transformed urothelial cells. Ex-
pression of this oncoprotein is also seen in neoplastic
blood vessels. E5 is found to be expressed intracytoplasmi-
cally with a typical juxtanuclear pattern suggesting Golgi
localization [44-46]. This observation has been made on
samples from different countries (Italy, Romania, Portugal,
Brazil), confirming the specific localization of E5 protein
in vivo [44,47,48]. The finding of E5 expression only in
cancer samples but not in normal tissue suggests that the
virus is involved in neoplastic processes and required for
it [46]. In addition, intratumoral colocalization of E5 and
E7 is noted, suggesting that cell transformation is trig-
gered by these oncoproteins in a synergistic manner
[49,50].
The molecular mechanism by which E5 induces cell
transformation lies in its binding to, and activation of
the PDGFβ-r, which is reflected by a potentiation of the
mitogenic response [51]. Interestingly, Borzacchiello et
al [52], have shown that in naturally occurring bovine
urinary bladder tumours BPV E5 is able to physically
interact with the PDGFβ-r and that the receptor is more
activated in cancer, confirming the role of the protein
complex in cancer development. Moreover, the binding
of the E5 and the PDGFβ-r induces the activation of dif-
ferent signal transduction pathways: the PDGFβ-r and
PI3K physically interact such as PDGFβ-r and the Grb2-
Sos complex. PI3K-Akt and Grb2-Sos-Mek-Erk signals
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lated (activated) Erk and Mek proteins are not signifi-
cantly overexpressed [53-55]. Cattle suffering from
urinary bladder cancer harbour BPV DNA in blood cells
where recently E5 expression has been demonstrated,
supporting the hypothesis that blood may constitute a
reservoir of the virus and suggesting a possible biological
activity of BPV in the blood of these animals [56,57].
It has been suggested that there is a possible direct
or indirect role of E5 oncoprotein in the inhibition of
intracellular communication in naturally occurring
cancer. In fact, the expression of Cx43 was shown to
be altered in different bovine urothelial neoplastic
lesions expressing E5 oncoprotein. The expression of
Cx43 was reduced in carcinoma in situ (CIS) samples,
and was lost in neoplastic invasive urothelial cells sug-
gesting a progressive loss of Cx43 during cancer devel-
opment [58].
It is worth noting that the BPV-2 E5 oncoprotein has
many biological characteristics similar to the viral HIV
Negative Regulatory Factor (Nef ) protein, which is
involved in iron metabolism via the Ferritin heavy chain
(HFE) [59]. The ferritin heavy chain is upregulated in E5
positive urothelial neoplasia [60]. The same samples ex-
press hepcidin (F Roperto, personal observations), an
antimicrobial hormone known to be a key regulator in
iron homeostasis. This observation suggests a possible
involvement of E5 in iron homeostasis during the devel-
opment of urothelial tumours.
During cell transformation, different cellular pathways
are activated, among these the arachidonic acid metabol-
ism seems to have an important role in tumour develop-
ment [61]. E5 activates arachidonic acid metabolism
independently of PDGFβ-r activation [62]. Interestingly,
in spontaneously arising bovine urinary bladder carcin-
omas the cyclooxygenase enzymes are overexpressed,
confirming a possible role of the E5 in the upregulation
of arachidonic acid metabolism also in vivo [45].
Finally E5-expressing bovine urinary bladder tumours
show activated calpain 3, suggesting a possible involve-
ment of this protein in urothelial carcinogenesis [63]. It
has been suggested that Calpain 3 plays a pro-apoptotic
role in cancer development [64].
Interestingly, BPV-2 E5 has also been found to be
expressed in urinary bladder tumours of water buffaloes
[65]. This observation thus suggests that also in this
case, the oncoprotein is involved in BPV-induced car-
cinogenesis independently of the infected species.
Finally BPV-2 E5 was found to be expressed and
physically interacted with PDGFβ-r in the uterine and
chorionic epithelium of the placenta in pregnant cows
suffering from naturally occurring papillomavirus-
associated urothelial bladder tumours. It is possible that
E5 action on PDGFβ-r is involved in organogenesis andneo-angiogenesis rather than in cell transformation
during pregnancy [66].
Equine sarcoid
BPV is the only known case among PVs to cross infect
other species. BPV-1/2 are able to infect equids inducing a
common dermatological neoplasm called sarcoid. There
are different clinical presentations of sarcoids (nodular, oc-
cult, fibroblastic, verrucous, malevolent and mixed, which
is a combination of several of these types) (Figure 1D), but
histologically they have all the same features: dermal pro-
liferation of spindle-shaped fibroblasts features forming
whorls and epidermal hyperplasia [1,67].
In sarcoids the E5 oncogene is transcriptionally active
and the protein is expressed in the neoplastic fibroblasts
and overlying hyperplastic epidermis where the virus com-
pletes its life cycle producing virions particles [68-71]. The
levels of E5 m-RNA are higher in the nodular type of sar-
coids as compared with the other clinical types, although
a recent report indicates that the highest levels of E5 DNA
are found in the lesions of horses suffering from an ag-
gressive form of disease i.e. multiple, rapidly growing
tumours of various type [72,73]. These data provide all
evidence of active BPV infection in sarcoids supporting
the role of E5 in cell transformation. Interestingly, se-
quence analysis of the E5 open reading frame of sarcoid-
associated BPV revealed several unique DNA sequence
variants, some of which are associated with increased
codon usage [74,75]. E5 sequence variations can influence
the cellular location and function of the oncoprotein and
are contributing factors to the pathogenesis of the disease.
Sarcoid lesions co-express BPV E5 and E7 oncoproteins in
neoplastic fibroblasts. E5 is localized in the cytoplasm in a
juxtanuclear position, whereas E7 is found expressed in
the cytoplasm and nuclei; the co-expression of E5 and E7,
suggests that these molecules may co-operate also in sar-
coid development. The role of E5 in naturally occurring
sarcoids has been largely investigated: E5 is found in mo-
lecular complex with the phosphorylated PDGFβ-r
(pPDGFβ-r) in sarcoids and the high levels of pPDGFβ-r
activate the PI3-K-Akt pathway and Grb2-Sos-Mek-Erk
pathway (G Borzacchiello, personal observations) such as
in bovine tumours [76]. It is therefore reasonable to as-
sume that E5 can activate the same signal transduction
pathways in bovine and equine species via the activation
of the PDGFβ-r.
E5 is also found transcriptionally active in blood cells
from sarcoid affected horses, thus suggesting a possible
contribution to virus spread. The BPV genomes and,
more importantly, the expression of E5 in equine inflam-
matory skin conditions suggest that BPV is also involved
in this type of disease [77].
Very little is known about the carcinogenic role of E7
in equine sarcoids, but it has recently been shown that
Figure 2 E5 and E7 can improve BPV activity by controlling the viral replication and persistence, and virus assembly. A schematic view
of the expression of the BPV E5 and E7 genes in epithelium. BPV gene expression is tightly regulated and strictly linked to epithelial
differentiation. In BPV naturally occurring epithelial tumours E5 and E7 colocalize in the basal layer. The expression of E5 and E7 in the basal layers
of the epithelium, would lead to sustained cell proliferation to favour virus-infected cells. E5 also could contribute to a successful BPV infection
establishment and persistence by inducing evasion of immune surveillance. In cutaneous fibropapillomas E7 is also expressed in the spinous
layers suggesting its implications in viral DNA amplification, instead E5 is expressed in more differentiated granular layers suggesting its
involvement in the late stages of virus life cycle (capsid synthesis). In fibropapillomas of the upper gastrointestinal tract E5 is expressed only in
the basal layers, moreover E7 is expressed also in more differentiated spinous and granular layers suggesting its involvement in viral DNA
amplification and in the late stages of virus life cycle. In bovine urinary bladder cancer E5 and E7 are expressed only in the basal layers.
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protein-associated factor (p600) and BPV E7, described
in vitro in cultured cells, takes place also in vivo [78].
Furthermore, intracellular signals involved in p600 func-
tional activity are not overexpressed, suggesting a differ-
ent functional activity of p600 in naturally occurring
carcinogenesis. It has also recently showed that E7 may
contribute to upregulate the expression of MMP-1 as
suggested by a previous in vivo study [79,80]. These
findings suggest that E7 may contribute to sarcoid cell
invasion process through upregulation of MMP.Figure 3 Schematic representation of cellular events mediated by BP
occurring tumours.Conclusions
PVs induced cell transformation is paradigmatically
based on the different contribution of the three viral
oncogenes E5, E6, and E7 affecting multiple cellular
pathways.
Most of the studies about PV induced oncogenesis
and the role of the viral oncogenes have firstly been
recognized in the BPV model system and later validated
for HPV.
The expression and functions of BPV E5 and E7 onco-
proteins have been largely investigated in naturallyV E5 and E7 responsible of cell transformation in naturally
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oncogene. Recent studies about the functions of E5
in vivo have on the one hand confirmed in vitro studies,
on the other hand have discovered new aspects.
The role of BPV E7 in cellular transformation has been
less investigated. To date, in vivo studies suggest a syner-
gism between E5 and E7: they cooperate in the BPV infec-
tion establishment and persistence as well as in controlling
cell proliferation and transformation processes (Figure 3),
suggesting that “two are better than one” in naturally
occurrying carcinogenesis.
Finally, in vivo studies about the expression and func-
tions of BPV oncoproteins in experimentally PV-induced
tumours are still relevant to better understand the onco-
genic potential of the virus and to gain new insights into
the interplay between PVs oncogenes.
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